On the Boards

Fibrocell Science Inc., an Exton biotechnology company focused on the development of regenerative cell therapy, has appointed Marc B. Mazur to its board. Mazur is the chairman of Elsworthy Capital Management Ltd., a London-based European equity hedge fund, and was the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard, Europe's largest hedge fund.